30 April 2008
Walcom Group Limited
("Walcom" or the "Company")
Acquisition of further interest
The Company announces that, on 25 January 2008, Walcom acquired a further 18
per cent. interest in Walcom Bio-Chem (Thailand) Company Limited ("Walcom
Thailand") for a cash consideration of (Thai Baht) THB1.8 million, which values
the entire share capital of Walcom Thailand at THB10 million. Walcom Thailand's
principal activity is the trading of chemical feed and additive products. The
acquisition increases Walcom's interest in the issued share capital of Walcom
Thailand from 37 per cent. to 55 per cent.
Financial information on Walcom Thailand
Walcom Thailand reported a profit before taxation of THB5,690,681 for the year
ended 31 December 2007 (year ended 31 December 2006: THB5,819,919).
The net assets of Walcom Thailand as at 31 December 2007 were THB7,248,951
(2006: THB6,508,270).
Enquiries:
Walcom Group Ltd +852 2494 0133
Francis Chi (Chief Executive Officer)
Albert Wong (Chief Financial Officer)
John East & Partners Limited +44 20 7628 2200
Jeffrey Coburn/Simon Clements
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.